Evaxion Appoints New Chief Executive Officer
Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has appointed Dr. Helen Tayton-Martin as its new Chief Executive Officer (CEO).
Dr. Tayton-Martin will assume her new role on November 24, 2025, and step down from Evaxion's Board of Directors. She brings extensive experience, including a background in molecular immunology and an MBA from London Business School.
Prior to joining Evaxion, Dr. Tayton-Martin co-founded Adaptimmune, a cancer-focused biotech company, where she served as Chief Operating Officer and later Chief Business & Strategy Officer for 17 years. During her tenure, she oversaw significant growth, collaborations, and financing, including the company's Nasdaq IPO.
Through her experience, Dr. Tayton-Martin has demonstrated her ability to lead and grow a company in the biotech industry.
Author's summary: Evaxion appoints Dr. Helen Tayton-Martin as CEO.